NRC
NRC HEALTHPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 5 National Research Corporation (NRC) announced it has surpassed $152…
- A Jun 22 Citizens initiates
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 12 added (0 new), 5 trimmed or exited.
- AnalystsBULLISH
4 of 5 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +5.8% to 725.6K shares. 8.1 days to cover, ≈3.3% of shares.
- TrendUPTREND
3% above its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 2 mentions: 0 bullish, 0 bearish. No setup call.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | TRIM | $4.1M |
| WELLS FARGO & COMPANY/MN | ADD | $3.9M |
| BANK OF AMERICA CORP /DE/ | TRIM | $1.8M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $1.7M |
| ENVESTNET ASSET MANAGEMENT INC | ADD | $1.4M |
| SEI INVESTMENTS CO | TRIM | $1.0M |
| ALPS ADVISORS INC | ADD | $1.0M |
| HSBC HOLDINGS PLC | DOUBLED | $634.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
5 analystsPrice is below the lowest target. Median implies +20%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jul 29, 2026 | Citizens MAINTAIN | Market Outperform |
| Jun 22, 2026 | Citizens INITIATE | Market Outperform |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 23, 2026 | Wheeler Penny Ann Director | AWARD | 7,697 sh |
| Jun 23, 2026 | NUNNELLY JOHN N Director | AWARD | 7,697 sh |
| Jun 23, 2026 | Lockhart Stephen H Director | AWARD | 7,697 sh |
| Jun 23, 2026 | Bhandari Parul Director | AWARD | 7,697 sh |
| Jun 23, 2026 | Berwick Donald M Director | AWARD | 7,697 sh |
| Mar 12, 2026 | Rau Jason Russell Executive Vice President | AWARD | 60,000 sh |
| Jan 22, 2026 | Lockhart Stephen H Director | AWARD | 8,819 sh |
| Jan 22, 2026 | Bhandari Parul Director | AWARD | 8,819 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.21 | $0.21–$0.21 | +0.0% | $35.8M |
| Next Q | $0.25 | $0.25–$0.25 | +0.0% | $36.6M |
| Current FY | $0.33 | $0.33–$0.33 | -2.9% | $142.6M |
| Next FY | $1.05 | $1.05–$1.05 | -1.9% | $154.5M |
Short side
FINRA· Oct 15, 2026SecBot reports
6 filings · 1 bullish · 0 bearish · 1 mixed · 4 neutral- NEUTRAL 8-KOct 27, 2026
NRC Health reported Q3 2026 revenue of $38.4M, up 11% YoY, and GAAP/Adjusted EPS of $0.21, in line with the consensus estimate of $0.21. TRCV grew 9% YoY to $154.1M, and operating cash flow was $8.0M.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KOct 19, 2026
NRC Health disclosed that CEO Trent Green was designated as interim principal financial officer on…
Monitor for any future 8-K disclosing a permanent CFO appointment or a departure of the prior CFO, which would indicate a more material governance shift.
- NEUTRAL 10-K/AApr 28, 2026
NRC Health filed an amended 10-K (Amendment No. 1) solely to provide Part III…
This administrative amendment introduces no new financial information or catalysts. Monitor the next quarterly filing for any operational updates under the new CEO, Trent Green.
- MIXED 8-KApr 28, 2026
NRC Health reported Q1 2026 revenue of $34.8M (+4% YoY), marking the first year-over-year revenue…
The TRCV acceleration (+13%) is a leading indicator for future revenue, but the sharp decline in operating margin (from 26% to 16%) warrants monitoring. Listen to the earnings call for commentary on…
All NRC filing & press-release reports (6)
- 8-K reportOct 27, 2026
- 8-K reportOct 19, 2026
- 10-K/A reportApr 28, 2026
- 8-K reportApr 28, 2026
- 8-K reportApr 20, 2026
- 8-K reportMar 5, 2026